Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.05B |
$72.46
+0.92%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$1.04B |
$10.13
-3.52%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.04B |
$15.08
-4.80%
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$1.02B |
$3.58
+6.07%
|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$1.02B |
$1.29
+0.78%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$1.01B |
$20.02
-0.47%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$1.00B |
$5.58
-3.79%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$1.00B |
$3.93
+6.50%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$997.47M |
$14.09
-5.97%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$995.49M |
$21.00
-0.83%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$990.48M |
$13.88
+0.14%
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$978.51M |
$26.81
-0.19%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$948.91M |
$4.58
-7.58%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$913.93M |
$16.77
+0.48%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$912.22M |
$12.79
-3.22%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$895.69M |
$12.21
+0.62%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$888.88M |
$5.39
+26.94%
|
|
PSNL
Personalis, Inc.
Biomarker-driven companion diagnostics align with PSNL's tumor-informed MRD testing framework.
|
$877.02M |
$9.89
+2.91%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$869.77M |
$18.85
-3.53%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$860.91M |
$19.14
-7.31%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$859.50M |
$28.10
-1.92%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics develops oncology therapeutics, with Amtagvi lifileucel representing an autologous TIL cell therapy for solid tumors.
|
$853.98M |
$2.35
+5.86%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$848.94M |
$20.18
+1.25%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$846.27M |
$20.83
-4.89%
|
|
VIR
Vir Biotechnology, Inc.
SiRNA-based therapeutics align with Oligonucleotide Therapeutics as a major modality.
|
$841.83M |
$6.07
-2.10%
|
Showing page 9 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
